|Day Low/High||0.70 / 0.74|
|52 Wk Low/High||0.70 / 7.13|
About a half hour to go before the markets open for the last trading day of the week. Acorda Therapeutics is up more than 10% in pre-market trading on rumors it could be the target of several potential suitors, including Biogen . Juno Therapeutics h...
The FDA granted fast track designation to imetelstat as a potential treatment for adults with with transfusion-dependent anemia.
A guide to keep track of all the companies reporting first quarter financial results today -- making sense of what's important and disregarding what's not.
Acorda Therapeutics announced positive results in a clinical trial for its drug CVT-301.
Ron Cohen, CEO of Acorda Therapeutics, says his company's pipeline is full and he is less worried about Obamacare than the FDA.